Kidney outcomes and safety of sodium-glucose cotransporter-2 inhibitor therapy in autosomal dominant polycystic kidney disease: systematic review and meta-analysis.
The first systematic evidence review reveals early promise for a kidney-protective drug class in polycystic kidney disease patients, historically excluded from treatment trials.
ADPKD patients—the most common hereditary kidney disease causing kidney failure—have been excluded from all pivotal SGLT2i trials, creating a major evidence gap for a drug class with proven CKD benefits. This PRISMA-registered meta-analysis provides the first systematic synthesis of available evidence, revealing encouraging but insufficient early signals that underscore the urgency of purpose-designed ADPKD trials for SGLT2 inhibitors.
What the study was
- Study design
- systematic_review_meta_analysis
- Population
- ADPKD patients treated with SGLT2 inhibitors
- Sample size
- 451
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Diabetes Res Clin Pract
Why it surfaced
ADPKD is a high-unmet-need rare disease (1:1000 population) with no disease-modifying treatments; first systematic evidence review for SGLT2i in this population; directly supports trial design decisions; important for cardiometabolic and rare disease watchlists.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.